Yesterday, March 17, 2016, 83 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.79 to $91,240,000.00.

Highlighted Stocks Traded by Insiders:

IPG Photonics (IPGP) - FREE Research Report

Ip Fibre Devices Ltd, who is 10% Owner at IPG Photonics, sold 25,000 shares at $89.80 on March 17, 2016. Following this transaction, the 10% Owner owned 7.0 million shares meaning that the stake was reduced by 0.36% with the 25,000-share transaction.

The shares most recently traded at $94.67, up $4.87, or 5.14% since the insider transaction. Historical insider transactions for IPG Photonics go as follows:

  • 4-Week # shares sold: 37,500
  • 12-Week # shares sold: 37,500
  • 24-Week # shares sold: 41,900

The average volume for IPG Photonics has been 411,300 shares per day over the past 30 days. IPG Photonics has a market cap of $4.7 billion and is part of the technology sector and electronics industry. Shares are up 4.26% year-to-date as of the close of trading on Thursday.

IPG Photonics Corporation develops and manufactures a range of high-performance fiber lasers, fiber amplifiers, and diode lasers used in various applications, primarily in materials processing worldwide. The company has a P/E ratio of 20.1. Currently, there are 6 analysts who rate IPG Photonics a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPGP - FREE

TheStreet Quant Ratings

rates IPG Photonics as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

IPG Photonics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AMC Entertainment Holdings (AMC) - FREE Research Report

Koch Howard Winchel Jr, who is Director at AMC Entertainment Holdings, sold 2,000 shares at $29.08 on March 17, 2016. Following this transaction, the Director owned 6,952 shares meaning that the stake was reduced by 22.34% with the 2,000-share transaction.

The shares most recently traded at $29.14, up $0.06, or 0.22% since the insider transaction. Historical insider transactions for AMC Entertainment Holdings go as follows:

  • 4-Week # shares sold: 10,250
  • 12-Week # shares sold: 10,250
  • 24-Week # shares sold: 11,500

The average volume for AMC Entertainment Holdings has been 300,500 shares per day over the past 30 days. AMC Entertainment Holdings has a market cap of $2.8 billion and is part of the services sector and media industry. Shares are up 20.75% year-to-date as of the close of trading on Thursday.

AMC Entertainment Holdings, Inc., through its subsidiaries, operates as a theatrical exhibition company in the United States and internationally. As of December 31, 2014, the company owned, operated, or held interests in 348 theatres with a total of 4,960 screens primarily in North America. The stock currently has a dividend yield of 2.76%. The company has a P/E ratio of 27.4. Currently, there are 9 analysts who rate AMC Entertainment Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMC - FREE

TheStreet Quant Ratings

rates AMC Entertainment Holdings as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, a generally disappointing performance in the stock itself and poor profit margins. Get the full

AMC Entertainment Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioDelivery Sciences International (BDSI) - FREE Research Report

De Paolantonio Ernest Robert, who is CFO, Secretary and Treasurer at BioDelivery Sciences International, bought 4,000 shares at $2.60 on March 17, 2016. Following this transaction, the CFO, Secretary and Treasurer owned 13,383 shares meaning that the stake was boosted by 42.63% with the 4,000-share transaction.

The shares most recently traded at $2.76, up $0.16, or 5.8% since the insider transaction. Historical insider transactions for BioDelivery Sciences International go as follows:

  • 4-Week # shares bought: 4,528
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 4,528
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 4,528
  • 24-Week # shares sold: 20,000

The average volume for BioDelivery Sciences International has been 1.1 million shares per day over the past 30 days. BioDelivery Sciences International has a market cap of $148.6 million and is part of the health care sector and drugs industry. Shares are down 43.53% year-to-date as of the close of trading on Thursday.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has a P/E ratio of 3.6. Currently, there are 6 analysts who rate BioDelivery Sciences International a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on BDSI - FREE

TheStreet Quant Ratings

rates BioDelivery Sciences International as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full

BioDelivery Sciences International Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.